2-ethoxy-1-vinylnaphthalene | 354810-21-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-ethoxy-1-vinylnaphthalene
• 英文别名: 1-ethenyl-2-ethoxynaphthalene
• CAS: 354810-21-2
• 化学式: C₁₄H₁₄O
• 分子量: 198.265
• InChiKey: ZMYZVOOBWUHOLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-ethoxy-1-vinylnaphthalene 、 二溴丙二酸二乙酯 在 fac-tris(2-phenylpyridinato-N,C2')iridium(III) 、 dipotassium hydrogenphosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以89%的产率得到ethyl 2-ethoxy-5-(2-ethoxynaphthalen-1-yl)furan-3-carboxylate
  参考文献：
  名称：

  Photoredox Divergent 1,2-Difunctionalization of Alkenes with gem-Dibromides

  摘要：

  The redox neutral photocatalytic divergent radical 1,2-difunctionalization of a wide array of structurally varied alkenes with gem-dibromides is presented. On the basis of the electronic effect of alkenes, predictable 1,2-carboxygenation and 1,2-carbohalogenation of alkenes are readily available regardless of steric effect. This protocol affords a practical approach to the biologically important furan skeleton. It is distinguished by good regioselectivity, good functional group compatibility, and late-stage modification and thus signifies an important step forward to divergent radical difunctionalization of alkenes.

  DOI：

  10.1021/acs.orglett.7b03371

文献信息

• Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives
  申请人：GRUENENTHAL GmbH

  公开号：US20030087926A1

  公开（公告）日：2003-05-08

  A substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivative of formula I 1 and salts thereof with pharmaceutically acceptable acids. Also disclosed are methods for making the derivative, and pharmaceutical compositions comprising the derivative. Methods for treating pain, migraine, and various other diseases using the pharmaceutical composition are also disclosed.

  一种公式I的1,2,3,4-四氢喹啉-2-羧酸衍生物及其与药用酸盐。还公开了制备该衍生物的方法，以及包含该衍生物的药物组合物。还公开了使用该药物组合物治疗疼痛、偏头痛和其他各种疾病的方法。
• Salts of substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compounds
  申请人：Gruenenthal GmbH

  公开号：US20040224969A1

  公开（公告）日：2004-11-11

  Salts of substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compounds, processes for their preparation, drugs containing these compounds and their use in treatment methods and for the preparation of drugs for specific indications, especially for the treatment of pain.

  1,2,3,4-四氢喹啉-2-羧酸替代盐的化合物，其制备方法，含有这些化合物的药物以及它们在治疗方法和制备特定适应症的药物中的应用，尤其是用于治疗疼痛。
• Piperidine derivatives having ccr3 antagonism
  申请人：Matsumoto Yoshiyuki

  公开号：US20070032525A1

  公开（公告）日：2007-02-08

  The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C 1 -C 6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

  本发明提供了具有抑制CCR3配体结合到靶细胞CCR3的活性的低分子化合物，即CCR3拮抗剂。本发明还提供了由下式（I）表示的化合物，其药学上可接受的酸加合物或药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的制药组合物，用于治疗或预防与CCR3相关的疾病，例如哮喘和过敏性鼻炎。
• 4,4-Disubstituted) piperidine derivatives having ccr3 antagonism
  申请人：Matsumoto Yoshiyuki

  公开号：US20070037851A1

  公开（公告）日：2007-02-15

  The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C 1 -C 6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

  本发明提供了具有抑制CCR3配体与靶细胞上CCR3结合活性的低分子化合物，即CCR3拮抗剂。本发明还提供了由下式（I）所表示的4,4-(二取代)哌啶衍生物，其药学上可接受的酸加合物或药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的药物组合物，用于治疗或预防与CCR3相关的疾病，如哮喘和过敏性鼻炎。
• SUBSTITUIERTE 1,2,3,4-TETRAHYDROCHINOLIN-2-CARBONSÄUREDERIVATE
  申请人：Grünenthal GmbH

  公开号：EP1254118A2

  公开（公告）日：2002-11-06